Partial dopamine loss enhances activated caspase-3 activity: Differential outcomes in striatal projection systems

Journal of Neuroscience Research

Volumn 82, Issue 3, 2005, Pages 387-396

  Ariano, Marjorie A ^a   Grissell, Anne E ^a   Littlejohn, F Craig ^a   Buchanan, Thomas M ^a   Elsworth, John D ^b   Collier, Timothy J ^c   Steece Collier, Kathy ^a,c  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Activated caspase 3; Limb use asymmetry; Parkinson's disease; Partial dopamine loss; Striatopallidal neurons

Indexed keywords

ACTIN; APOPTOSOME; CASPASE 3; DOPAMINE; OXIDOPAMINE; SUBSTANCE P; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CELL DEATH; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; ENZYME ACTIVITY; FOREFOOT; GLOBUS PALLIDUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; APOPTOSIS; CASPASE 3; CASPASES; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOPAMINE; EFFERENT PATHWAYS; ENKEPHALINS; ENZYME ACTIVATION; MALE; MITOCHONDRIAL PROTEINS; NERVE DEGENERATION; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; SYMPATHOLYTICS; TYROSINE 3-MONOOXYGENASE; UP-REGULATION;

EID: 27644543123     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.20644     Document Type: Article

References (51)

1. Albin RL, Greenamyre JT. 1992. Alternative excitotoxic hypotheses. Neurology 42:733-738.
2. Arbuthnott GW, Ingham CA, Wickens JR. 2000. Dopamine and synaptic plasticity in the neostriatum. J Anat 196:587-596.
3. 1A receptor distribution. Synapse 27:313-321.
4. Ariano MA, Cepeda C, Calvert CR, Flores-Hernandez J, Hernandez-Echeagaray E, Klapstein GJ, Chandler S, Aronin N, DiFiglia M, Levine MS. 2005a. Striatal potassium channel dysfunction in Huntington's disease transgenic mice. J Neurophysiol 93:2565-2574.
5. Ariano MA, Wagle N, Grissell AE. 2005b. Neuronal vulnerability in mouse models of Huntington's disease: membrane channel protein changes. J Neurosci Res 80:634-645.
6. Barneoud P, Parmentier S, Mazadier M, Miquet JM, Boireau A, Dubedat P, Blanchard JC. 1995. Effects of complete and partial lesions of the dopaminergic mesotelencephalic system on skilled forelimb use in the rat. Neurosci 67:837-848.
7. Beal MF. 2001. Experimental models of Parkinson's disease. Nat Rev Neurosci 2:325-332.
8. Bergstrom BP, Schertz KE, Weirick T, Nafziger B, Takacx SA, Lopes KO, Massa KJ, Walker QD, Garris PA. 2001. Partial, graded losses of dopamine terminals in the rat caudate-putamen: an animal model for the study of compensatory adaptation in preclinical parkinsonism. J Neurosci Methods 106:15-28.
9. Bilsland J, Roy S, Xanthoudakis S, Nicholson DW, Han Y, Grimm E, Hefti F, Harper SJ. 2002. Caspase inhibitors attenuate 1-methyl-4-phenylpyridinium toxicity in primary cultures of mesencephalic dopaminergic neurons. J Neurosci 22:2637-2649.
10. Braak H, Del Tredici K, Rub UJ, de Vos RA, Jansen Steur ENH, Braak E. 2003. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211.
11. Breysse N, Amalric M, Salin P. 2003. Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in Parkinsonian rats. J Neurosci 23:8302-8309.
12. Calabresi P, Mercuri NB, Sancesario G, Bernardi G. 1993. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 116:433-452.
13. Calabresi P, Centonze D, Bernardi G. 2000. Electrophysiology of dopamine in normal and denervated striatal neurons. TINS 23:S57-S63.
14. Cannon JR, Keep RF, Hua Y, Richardson RJ, Schallert T, Xi G. 2005. Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson's disease model. Neurosci Lett 373:189-194.
15. Elsworth JD, Deutch AY, Redmond DE Jr, Taylor JR, Sladek JR Jr, Roth RH. 1989. Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- treated primates: biochemical changes in striatal regions. Neuroscience 33:323-331.
16. Emmi A, Rajabi H, Stewart J. 1996. Behavioral and neurochemical recovery from partial 6-hydroxydopamine lesions of the substantia nigra is blocked by daily treatment with glutamate receptor antagonists MK-801 and CPP. J Neurosci 16:5216-5224.
17. Fiskum G, Starkov A, Polster BM, Chinopoulos C. 2003. Mitochondrial mechanisms of neural cell death and neuroprotective interventions in Parkinson's disease. Ann N Y Acad Sci 991:111-119.
18. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL. 2003. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A 100:10032-10037.
19. Garnier P, Ying W, Swanson RA. 2003. Ischemic preconditioning by caspase cleavage of poly(ADP-ribose) polymerase I. J Neurosci 23:7967-7973.
20. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr, Sibley DR. 1990. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250:1429-1432.
21. Graybiel A. 2000. The basal ganglia. Curr Biol 10:R509-R511.
22. Greenamyre JT, MacKenzie G, Peng TI, Stephans SE. 1999. Mitochondrial dysfunction in Parkinson's disease. Biochem Soc Symp 66:85-97.
23. Ingham CA, Hood SH, Arbuthnott GW. 1989. Spine density on neostriatal neurons changes with 6-hydroxydopamine lesions and with age. Brain Res 503:334-338.
24. Kirik D, Rosenblad C, Bjorklund A. 1998. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 152:259-277.
25. Kroemer G, Reed JC. 2000. Mitochondrial control of cell death. Nat Med 6:513-519.
26. Langston JW, Ballard PA, Tetrud JW, Irwin I. 1983. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980.
27. Lehr H-A, van der Loos CM, Teeling P, Gown AM. 1999. Complete chromagen separation and analysis in double immunohistochemical stains using Photoshop-based image analysis. J Histochem Cytochem 47:119-127.
28. McLaughlin B, Hartnett KA, Erhardt JA, Legos JJ, White RF, Barone FC, Aizenman E. 2003. Caspase 3 activation is essential for neuroprotection in preconditioning. Proc Natl Acad Sci U S A 100:715-720.
29. McNeill TH, Brown SA, Rafols JA, Shoulson I. 1988. Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease. Brain Res 455:148-152.
30. Mitchell IJ, Cooper AJ, Griffiths MR. 1999. The selective vulnerability of striatopallidal neurons. Prog Neurobiol 59:691-719.
31. Mochizuki H, Hayakawa H, Migita M, Shibata M, Tanaka R, Suzuki A, Shimo-Nakanishi Y, Urabe T, Yamada M, Tamayose K, Shimada T, Miura M, Mizuno Y. 2001. An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as anti-apoptotic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A 98:10918-10923.
32. Morelli M, Di Chiara G. 1987. Agonist-induced homologous and heterologous sensitization to D1 and D2 dependent contraversive turning. Eur J Pharmacol 141:101-107.
33. Nagatsu T. 2000. Parkinson's disease: changes in apoptosis-related factors suggesting possible gene therapy. J Neural Transm 109:731-745.
34. Nicklas WJ, Heikkila RE. 1985. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-12,3,6-tetrahydropyridine. Life Sci 36:2503-2508.
35. Nisenbaum LK, Crowley WR, Kitai ST. 1996. Partial striatal dopamine depletion differentially affects striatal substance P and enkephalin messenger RNA expression. Brain Res Mol Brain Res 37:209-216.
36. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Macias R, Alvarez L, Guridi J, Vitek J, DeLong M. 2000. Pathophysiologic basis of surgery for Parkinson's disease. Neurology 55:S7-S12.
37. Oo TF, Siman R, Burke RE. 2002. Distinct nuclear and cytoplasmic localization of caspase cleavage products in two models of induced apoptotic death in dopamine neurons of the substantia nigra. Exp Neurol 175:1-9.
38. Pang Z, Ling GY, Gajendiran M, Xu ZC. 2001. Enhanced excitatory synaptic transmission in spiny neurons of rat striatum after unilateral dopamine denervation. Neurosci Lett 308:201-205.
39. Paxinos G, Watson SJ. 1986. The rat brain in stereotaxic coordinates. Sydney: Academic Press.
40. Riederer P, Wuketich S. 1976. Time course of nigrostriatal dopamine degeneration in Parkinson's disease. J Neural Transm 38:277-301.
41. Rodriguez-Oroz MC, Rodriguez M, Guridi J, Mewes K, Chockkman V, Vitek J, DeLong MR, Obeso JA. 2001. The subthalamic nucleus in Parkinson's disease: somatotopic organization and physiological characteristics. Brain 124:1777-1790.
42. Rosenberg NL, Myers JA, Martin WRW. 1989. Cyanide-induced parkinsonism: clinical, MRI, and 6-fluorodopa PET studies. Neurology 39:142-144.
43. Schallert T, Tillerson JL. 1999. Intervention strategies for degeneration of dopamine neurons in Parkinsonism: optimizing behavioral assessment of outcome. In: Emerich DF, Dean RL III, Sanberg PR, editors. Central nervous system diseases. Totowa, NJ: Humana, p 131-151.
44. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST. 2000. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39:777-787.
45. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Parnov AV, Cookson MR, Greenamyre JT. 2002. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered α-synuclein metabolism and oxidative damage. J Neurosci 22:7006-7015.
46. Tanaka H, Yokota H, Jover T, Cappuccio I, Calderone A, Simionescu M, Bennett MVL, Zukin RS. 2004. Ischemic preconditioning: neuronal survival in the face of caspase-3 activation. J Neurosci 24:2750-2759.
47. Tillerson JL, Cohen AD, Philhower J, Miller GW, Zigmond MJ, Schallert T. 2001. Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J Neurosci 21:4427-4435.
48. Waldmeier PC. 2003. Prospects for antiapoptotic drug therapy of neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psych 27:303-321.
49. Wang H, Shimoji M, Yu SW, Dawson TM, Dawson VL. 2003. Apoptosis inducing factor and PARP-mediated injury in the MPTP mouse model of Parkinson's disease. Ann N Y Acad Sci 991:132-139.
50. Yoshida H, Kong YY, Youshida R, Elia AJ, Hakem A, Hakem R, Penninger JM, Mak TW. 1998. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell 18:739-750.
51. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. 1997. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90:733-739.